CCK-B Receptor Antagonists For The Treatment Of Depression Especially Chronic Pain Comorbid Depression Of Elderly 

Project: Research

View graph of relations


Globally, the population is aging rapidly. Chronic pain and depression are highly prevalent in elderly populations. It is estimated that 13% of the elderly population will suffer simultaneously from the two conditions. Nearly all the antidepressant drugs are currently used have a lot of side effects and tolerance. The proposed project aims at understanding the underlying mechanism of chronic pain related depression and developing the potential treatment for the comorbid depression. Cholecystokinin (CCK) is one of the most abundant neuropeptides in the mammalian nervous system. It was considered involved in aversive memory formation and the progression of depression. CCK antagonists can enhance the analgesic effect of opiate. Recently, our preliminary results show that CCK-B receptor knock-out mice exhibited great relief of depression in learned helplessness behavior tests. We also found that most antidepressants showed similar effect of blocking memory formation as CCK antagonists. In the present study we will carry out a large-scale of experiments to find out the brain mechanism of CCK antagonists for treating chronic pain and depression for the elderly. Finally, we will finish the preparation and document work for Phase 2 clinical trial for repurpose of YF476 as antidepressant.


Project number9440217
Grant typeITF
Effective start/end date1/07/1931/08/22